Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 16 of 16 for “"PCSK9"”.
-
Characterization of PCSK9-mediated LDLR Degradation in Hepatic and Fibroblast Cells
… proprotein convertase subtilisin/kexin type 9 (PCSK9) mediates degradation of low-density lipoprotein receptors (LDLR) indicates a critical role in LDL metabolism. PCSK9 is a secreted protein that binds to the epidermal growth factor-like (EGF)-A domain of LDLR and directs the receptor for …
-
Characterization of the Non-Proteolytic Mechanism and Cellular Site of Action of PCSK9-Mediated Degradation of the Low-Density Lipoprotein Receptor
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is a serine protease that has emerged as a central regulator of plasma low-density lipoprotein cholesterol levels. Here, it is demonstrated that PCSK9 is secreted into the blood and that the secreted PCSK9 binds and degrades LDLRs in liver. To …
-
The New Role of Proprotein Convertase Subtilisin/Kexin Type 9: A Connection of Proprotein Convertase Subtilisin/Kexin Type 9, Apolipoprotein B, and Autophagy
… convertase subtilisin/kexin type 9 (<em>PCSK9</em>) is a newly discovered gene, playing an important role in LDL metabolism. Gain-of-function mutations of <em>PCSK9</em> lead to hypercholesterolemia and loss-of-function mutations of <em>PCSK9</em> are associated with decrease of LDL …
-
Microarray Analysis Identifies Novel Cholesterol Regulated Genes, Including Pcsk9 Which Regulates LDL Receptor Function and LDL Cholesterol Levels
… genes, Proprotein convertase subtilisin kexin 9 (Pcsk9) was cloned from mouse liver. Pcsk9 was found to be synthesized as a pro-form in the endoplasmic reticulum (ER) and expressed as a processed form in the trans-Golgi network. In mice, Pcsk9 was found to be expressed mainly in the liver. …
-
Type 2 diabetes mellitus and dyslipidaemia: effects of genetic variation in African populations
… proprotein convertase subtilisin/kexin type 9 (PCSK9). ApoE and PCSK9 are involved in clearance of lipoproteins and therefore, influence lipid profiles. Association between ApoE and T2DM in cardiovascular diseases have been widely reported. PCSK9 on the other hand is emerging as an important …
-
Germline Genetic Modulator of Cancer Metastasis
… identified a common missense germline variant in PCSK9 (rs562556, V474I) that associates with reduced survival in breast cancer cohorts from multiple countries. This highly prevalent variant is homozygous in ~70% of people of European ancestry. Genetic modeling of this gain-of-function single …
-
APOE, PCSK9, and CETP genetic variants as potential biomarkers of dyslipidaemia in black South Africans with Type 2 Diabetes Mellitus
… proprotein convertase subtilisin/kexin type 9 (PCSK9), and cholesteryl ester transfer protein (CETP) are key regulators of plasma cholesterol levels. Thus, genetic variation in the genes coding for these proteins contributes to dyslipidaemia. In this study, a cohort of black South African Type 2 …
-
PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ATHEROSCLEROSIS AND EXTRACELLULAR VESICLES ¿ EXPERIMENTAL AND CLINICAL EVIDENCE
… Proprotein convertase subtilisin/kexin type 9 (PCSK9) is expressed and secreted by VSMCs. This study aimed to unravel the role of PCSK9 on VSMCs-derived EVs in terms of content and functionality. EVs were isolated from human VSMCs overexpressing human PCSK9 (VSMCPCSK9-EVs) and tested on …
-
Molecular Mechanisms of SURF4- mediated Protein Secretion
… isoforms, a previously described SURF4 cargo, PCSK9, which exposes ER-ESCAPE after propeptide autocleavage, exclusively employs SEC24A. I show that this discrepancy is due to a PCSK9 requirement for a co-receptor, TMED10. Using a protein-protein interaction assay and various SEC24 and SURF4 …
-
Investigation of molecular and cellular events associated with beta cell function and elucidation of extracellular RNAs as potential biomarker for diabetes
… validated using qRT-PCR including Txnip, Gcg and Pcsk9. Txnip was up-regulated whereas Gcg and Pcsk9 were down-regulated in MIN6 B1(Non-GSIS) compared to MIN6 B1(GSIS). siRNA and shRNA silencing of Txnip in MIN6(H) (non-responsive) significantly increased the GSIS. Over-expression of Txnip cDNA in …
-
SCREENING AND IDENTIFICATION OF NEW FOOD DERIVED PEPTIDES WITH MULTI-TARGET CHOLESTEROL-LOWERING ACTIVITY
… In detail, peptides derived from lupin showed PCSK9 inhibitory activity. Among these, the most active peptide, known as P5 (LILPHKSDAD), reduced the protein-protein interaction between PCSK9 and LDLR with an IC50 equals to 1.6 μM and showed a dual hypocholesterolemic activity, since it shows …
-
Development of polymeric nanoparticle vaccines for immunostimulation
… discovered through in silico modeling for human PCSK9, a plasma protein that plays an important role in LDL cholesterol (LDL-c) levels in the blood, our nanoparticle allows selective orientation through biotin-streptavidin conjugation. Upon vaccination with CPG, selected synthetic epitopes …
-
COMPUTATIONAL DESIGN OF PEPTIDES AND PEPTIDOMIMETICS AS POTENTIAL THERAPEUTIC AGENTS TO SATISFY PRESSING MEDICAL NEEDS
… endowed with a dual inhibitory activity against PCSK9 and HMG-CoAR protein targets, both crucial for the treatment of hypercholesterolemia (case study 2). In the case study 3, several computational approaches have been applied to discover ligands with potential anticancer activity capable of …
-
Detection of Genes Influencing Chronic and Mendelian Disease Via Loss-of-Function Variation
… two relationships in well-studied genes (<em>PCSK9</em> and <em>APOC3</em>) and identified eight new loci. Novel relationships included elevated fasting glucose in heterozygous carriers of LOF variation in <em>TXNDC5</em>, which encodes a biomarker for type 1 diabetes progression, and apparent …
-
USE OF MULTIPLE ANALYTIC APPROACHES TO IDENTIFY NEW MARKERS/RISK FACTORS FOR CARDIOVASCULAR DISEASES AND EVALUATE THEIR ROLE AS POSSIBLE PHARMACOLOGICAL TARGETS
… riscontrato che tra le LLT, gli inibitori di PCSK9 (-6,41 mg/dL, 95%CI [-7,57 a -5,24]) e gli inibitori di CETP (-6,60 mg/dL, 95%CI [-9,26 a -3,95]) riducevano significativamente i livelli di Lp(a). D'altra parte, le statine (-0,65 mg/L, 95%CI [da -0,87 a -0,43]), l'acido bempedoico (-0,43 …